Rocket One Q2 Loss Widens to $3.8M; Cash at $7.9M
RKTO sits 54% above its 52-week low of $0.489.
Summary
Rocket One's Q2 loss widened to $3.8M as it transitions to AI infrastructure. Cash of $7.9M provides runway, but ongoing ATM sales and a new private placement highlight continued dilution risk.
Key Events · Earnings and Guidance · RKTO
-
Q2 Net Loss Widens
Net loss of $3.83M for Q2 2026 vs $2.20M in Q2 2025; six-month loss of $6.53M vs $5.68M.
-
Cash Runway
Cash and cash equivalents of $7.89M as of June 30, 2026; management states sufficient for at least 12 months.
-
ATM Sales Continue
Sold 4,193,178 shares for net proceeds of $5.85M in H1 2026; additional 1,712,947 shares for $1.94M after quarter-end.
-
April Private Placement
Issued 2,857,144 shares at $0.70 with warrants exercisable at $0.85; net proceeds of $1.61M.
Analysis · RKTO · Life Sciences
Rocket One reported a Q2 net loss of $3.83 million, up from $2.20 million a year earlier, as the company pivots from biopharma to AI semiconductor infrastructure. Cash stands at $7.89 million, enough for at least 12 months per management, but the company continues to rely on equity sales — it raised $5.85 million via its ATM in H1 and another $1.94 million after quarter-end. The filing also reveals a $250,000 SAFE investment in Placeve and a NASA license agreement, underscoring the strategic shift.
At the time of this filing, RKTO was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.49 to $2.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.